Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions.

In April 2025, the U.S. Food and Drug Administration (FDA) approved Teva's digital inhaler, which combines built-in sensors with a companion mobile app to assist in managing asthma and COPD symptoms.

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers ... with asthma and COPD under a 510 ...

People with asthma, chronic obstructive pulmonary disease (COPD), and certain other respiratory conditions typically receive Medicare coverage for inhalers. To receive coverage, a person must have ...

All patients were treated with standard-of-care therapy, including medium-to-high doses of inhaled corticosteroids and up to ... Lunsekimig, a candidate for asthma and COPD across inflammation ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

In addition to cigarette smoke, cigar smoke, pipe smoke, and secondhand smoke can cause COPD. Your risk of COPD is even greater if you have asthma and ... taken through an inhaler or nebulizer.

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition ... to-high doses of inhaled ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

Background: The proliferation of inhaler devices has resulted in a ... When selecting an aerosol delivery device for patients with asthma and COPD, the following should be considered: device ...